| MultiHance Official FDA information, side effects and uses. Accurate, FDA approved MultiHance information for healthcare professionals and patients - brought to you by Drugs.com. Read More |
| Multihance (Gadobenate Dimeglumine Injection) Drug Information ... Learn about the prescription medication Multihance (Gadobenate Dimeglumine Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and ... Read More |
| MultiHance® from Bracco Diagnostics, Inc. - Cardiovascular ... MultiHance® from Bracco Diagnostics, Inc. - Cardiovascular Product Details - Medcompare. Medcompare - The Buyer's Guide for Medical Professionals Read More |
| MultiHance: Frequently Asked Questions - MRIsafety.com. MRI safety ... disclaimer. Please Read! MultiHance: Frequently Asked Questions. QUESTION How does the safety profile of MultiHance compare to the other currently available ... Read More |
| MultiHance (SPC) | Drugs.com Summary of Product Characteristics for MultiHance. Detailed information for prescribers and healthcare professionals. Read More |
| Magnetic Resonance TIP - MRI Database: 'MultiHance' Description, information and specification (compound, contrast effect, relaxivity, etc.), further resources and news for the MRI contrast agent/media MultiHance from ... Read More |
| The domain multihance.com is registered by Eastitaly 50 MB disk space; Available either as POP3 or IMAP; Read with your client and with WebMail; Forwarding to other address; Catch-All option; Antivirus & Antispam protection Read More |
| MULTIHANCE (GADOBENATE DIMEGLUMINE) INJECTION, SOLUTION [BRACCO ... HIGHLIGHTS OF PRESCRIBING INFORMATION: These highlights do not include all the information needed to use MultiHance safely and effectively. See full prescribing ... Read More |
| Gadobenic acid - Wikipedia, the free encyclopedia InChI=1S/C22H31N3O11.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H ... Read More |
| MultiHance Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committee Gaithersburg, MD - December 8, 2009 Read More |
